Capital Cell

Inrobics is a company that focuses on enhancing rehabilitation through the integration of artificial intelligence and social robots. Their cloud-based platform is designed to assist individuals with functional or neurological limitations, offering personalized treatment options that can be utilized in rehabilitation centers or within the comfort of the patient's home. Inrobics' technology aims to improve the quality of rehabilitation by addressing the specific needs of clients affected by brain damage, neurodevelopmental disorders, or related conditions. Through their innovative approach, Inrobics provides not only rehabilitation treatments but also support and education, fostering overall well-being for those in need.

MOWOOT is a Non-pharmacological & Non-invasive solution for people suffering from chronic constipation. Its solution is a wearable medical device, which provides an automatic colon-specific massage similar to the manual abdominal massage administered by health professionals. MOWOOT utilizes advanced pneumatic technology to treat and prevent chronic slow transit constipation without colon cleansing supplements, enemas, and laxatives. The company emerged out of the MOEBIO dHEALTH program, which is inspired by Stanford Biodesign and Kaospilot Design and Business School from Denmark. MOWOOT was founded in 2014 and is based in Barcelona, Spain.

Kintsugi Therapeutics is a preclinical biopharmaceutical company focused on developing therapies for liver conditions, including Non-Alcoholic Steatohepatitis (NASH). The company specializes in creating endoplasmic reticulum (ER) stress inhibitors aimed at addressing liver diseases and other related health issues. By targeting the regulation of ER stress, Kintsugi Therapeutics seeks to provide effective treatment options that can enhance the quality of life for patients suffering from these conditions.

Developer of a medical device designed to offer quality three-dimensional ultrasound images of the breast to improve diagnostics. The company's device provides services from data transfer to the cloud, to image reconstruction and image visualization and analysis via a user-friendly user interface, enabling medical professionals to monitor breast tumors without exposing the patient to harmful ionizing radiation.

Corify Care SL develops a medical device that non-invasively can see the electrical activity of the heart without the need of catheters or complex MRI/CT mappings. It offers ACORYS, a non-invasive electrocardiographic imaging device that resolves the main shortcomings of existing solutions to identify the optimal treatment in each patient with atrial fibrillation. The company was incorporated in 2019 and is based in Madrid, Spain.

Aortyx is a Spanish company based in Teià, established in 2018 by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona. It specializes in the development of endovascular devices aimed at treating vascular diseases, particularly aortic dissections. Aortyx's innovative technology emphasizes tissue regeneration rather than artificial replacement. By mimicking the biomechanical environment of the aorta, the company's devices create an optimal setting for cell migration and proliferation, utilizing a bioresorbable platform that closely resembles the natural dynamics of the aorta. This approach allows medical professionals to address vascular diseases more effectively.

Aortyx is a Spanish company based in Teià, established in 2018 by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona. It specializes in the development of endovascular devices aimed at treating vascular diseases, particularly aortic dissections. Aortyx's innovative technology emphasizes tissue regeneration rather than artificial replacement. By mimicking the biomechanical environment of the aorta, the company's devices create an optimal setting for cell migration and proliferation, utilizing a bioresorbable platform that closely resembles the natural dynamics of the aorta. This approach allows medical professionals to address vascular diseases more effectively.

Aortyx is a Spanish company based in Teià, established in 2018 by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona. It specializes in the development of endovascular devices aimed at treating vascular diseases, particularly aortic dissections. Aortyx's innovative technology emphasizes tissue regeneration rather than artificial replacement. By mimicking the biomechanical environment of the aorta, the company's devices create an optimal setting for cell migration and proliferation, utilizing a bioresorbable platform that closely resembles the natural dynamics of the aorta. This approach allows medical professionals to address vascular diseases more effectively.

Ekuore is a technology company based in Valencia, Spain, founded in 2012, that specializes in the design, development, and marketing of medical devices that integrate health services with mobile technologies. The company focuses on creating mHealth devices aimed at revolutionizing sanitary teleassistance, allowing for efficient and cost-effective monitoring and control of patients. Ekuore's flagship product is a digital electronic stethoscope designed to track and monitor patients' conditions, particularly in diagnosing cardiovascular diseases. This device compares physiological parameters against a comprehensive database to provide objective diagnoses, enabling hospitals to conduct secure digital consultations and enhance patient care.

QMENTA is a cloud-based platform focused on medical image analysis and visualization, specifically aimed at enhancing the diagnosis and treatment of brain diseases. By enabling specialists such as neurologists, neurosurgeons, and neuroradiologists to upload and process medical images through a user-friendly interface, QMENTA facilitates advanced analyses and visualization without the need for software installation. The platform houses patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms, allowing for efficient data management and insights extraction from large-scale brain images. Additionally, it supports compliance with regulatory standards, ensuring the privacy and security of patient data. Researchers worldwide utilize QMENTA's scalable platform to advance their understanding and analysis of extensive image datasets, ultimately accelerating the development of new treatments for brain conditions.

Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.

LAMINAR PHARMA is a pioneering biopharmaceutical company that focuses on the discovery, rational design and initial clinical development of a new generation of medicines associated with a novel therapeutic approach: Membrane Lipid Therapy (MLT).

Operator of a biomedical research company intended to produce implantable medical devices. The company's cost-effective patented technology allows the creation of nanostructures on the surface, preventing bacteria attachment and, therefore, bacteria colonization for a higher lifetime, lower associated costs, and no post-implantation problems without adverse effects on the patients, enabling patients to get antibacterial coatings wide range of medical devices.

Rithmi is a privately held company focused on heart health and stroke prevention through innovative arrhythmia detection technologies. The company has developed a device that records data and detects arrhythmias in real time by measuring the intensity of light reflected on the skin's surface, creating a waveform of heart pulses. This technology offers a level of accuracy comparable to an electrocardiogram (ECG), making it a significant advancement in the diagnosis of atrial fibrillation. After successful pilot tests of its prototype, Rithmi is poised to expand into new markets in Europe, demonstrating strong potential for rapid growth and a commitment to enhancing patient care through its unique approach to Computational Predictive Care.

RheoDx is a developer of a diagnostic medical device focused on enhancing the quality of life for hematology patients. The company's innovative device measures the behavior of blood in motion, utilizing just a small drop of blood to detect changes in rheological properties. These changes can indicate abnormalities in red blood cell morphology and rigidity, which are linked to various diseases, including blood coagulation disorders, malignant homeopathies, malaria, and hereditary anemias. Designed for simplicity and portability, the device can be used at the point of care or in home settings, allowing patients to perform tests themselves. This approach not only facilitates timely monitoring but also aims to improve patient outcomes at competitive prices.

DERMA INNOVATE, S.L. is a Biotechnology Company, created and owned by Cannan research & Investment, focused on obtaining a series of advanced compounds in the area of skin and hair regeneration.

Fesia Technology S.L. is a medical device company based in Donostia, Spain, focused on neurorehabilitation solutions for individuals affected by injuries and neuromuscular diseases, such as stroke, spinal cord injuries, cerebral palsy, and multiple sclerosis. Since its establishment in 2016, the company has developed innovative devices utilizing functional electrical stimulation technology. One of its key products, Fesia Walk, is designed specifically for patients with foot drop, offering rehabilitation support through a unique electrode matrix system. Fesia aims to enhance the rehabilitation process by providing advanced medical devices that cater to patients at various stages of recovery, thereby improving their overall quality of life.

Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.

Arcis Biotechnology Limited specializes in the development and commercialization of nucleic acid sample preparation solutions. The company offers a range of ready-to-use kits designed for the rapid extraction of nucleic acids from various biological samples, including whole blood, saliva, and cells from plants and animals. Their products, such as the Arcis Sample Prep Kit and the Arcis Blood Kit, enable users to obtain genetic material in less than three minutes without the need for laboratory equipment or extensive sample preparation. The technology facilitates the extraction of DNA and RNA from small sample volumes, with applications in point-of-care diagnostics, forensic analysis, and genomic research. Arcis Biotechnology provides its solutions through distributors in multiple countries, including the United Kingdom, India, and Belgium. Established in 2013 and based in Warrington, United Kingdom, the company was formerly known as Arcis Molecular Limited before rebranding in 2018.

Adan Medical Innovation, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2014. The company specializes in developing medical devices to assist with the management of anaphylaxis, particularly for individuals who require epinephrine. Its flagship product, Anapphylaxis, is a smart case for epinephrine auto-injectors that connects to a mobile application via Bluetooth. This device not only monitors the condition of the epinephrine but also alerts users if they forget their injector and activates a pre-defined action plan in case of an anaphylactic event, providing clear instructions for drug administration and notifying designated contacts with the user's location. Additionally, Adan Medical is working on WE SAVE, a smart box designed for public spaces that contains epinephrine auto-injectors, further enhancing the safety and management of severe allergic reactions.

Cebiotex, S.L. is a company based in Terrassa, Spain, specializing in drug delivery solutions utilizing electrospun nanofiber technology. Founded in 2012, Cebiotex focuses on the development and characterization of preclinical nonwoven nanofiber membranes designed for the controlled release of active agents. These membranes are aimed at providing local treatment options for unresectable tumors, enhancing therapeutic efficacy for patients. Through its manufacturing capabilities and contract research services, Cebiotex supports medical professionals in addressing the challenges associated with treating inoperable cancerous lesions.

Davalor Salud, S. L., founded in 2011 and based in Aranguren, Spain, specializes in vision testing and health services. The company has developed a unique machine, the Evaluador de Visión Automatizado, which employs 3D video games to autonomously detect vision problems. In addition to diagnostic capabilities, Davalor Salud provides analysis, diagnosis, and reports on users' visual health. The firm's services aim to improve functional visual health and accessibility, offering both diagnosis and visual training to enhance the quality of life for individuals with visual impairments.

MJN improves the quality of life of people suffering from epilepsy thanks to our wearable ear piece that performs an EEG of the patient. By applying AI algorithms, MJN-SERAS is able to interpret the brain signal, record epileptic seizures, objectively improve the medical monitoring and permanently assess the risk of suffering an epilepsy seizure

Biohope is dedicated to the development of diagnostic and therapeutic solutions for organ transplantation.

Vytrus Biotech SL engages in development, production, and commercialization of active ingredients from plant stem cells. The company offers cosmetic products such as plasma rich in cell factors and phyto peptidic fractions; dermatologic products; and tailor made products. Vytrus Biotech SL was formerly known as Phyture Biotech SL and changed its name to Vytrus Biotech SL in 2016. The company was founded in 2009 and is based in Barcelona, Spain.

Absynth Biologics Limited focuses on discovering and developing vaccines and therapeutic antibodies aimed at preventing and treating bacterial infections. The company targets significant pathogens, including Staphylococcus aureus, Clostridium difficile, and Streptococcus pyogenes, using a novel platform that identifies protein antigen targets. This approach leverages the immune system through a dual-action mechanism, which includes direct antibacterial effects from antibody-mediated inhibition and the activation of immune effector functions to eliminate bacteria. Founded in 2007 and based in Alderley Edge, United Kingdom, Absynth Biologics is dedicated to advancing immunological prophylaxis and therapy to combat bacterial infections.

Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Our target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory disease affecting the lung, liver, kidney, eye, bone and cartilage.

TBIOM biotechnological startup that aims to develop sustainable medical products and solutions to help large sectors of the population. TBIOM is working on the development of different electronic mhealth devices such as the control system for chronic alcoholism ETHAXIP (intra-oral device) or the DALVC system for performing continuous bladder washes in hospital centers. This last device is being developed jointly with Vecmedical and Vall d'Hebrón Hospital . In addition, TBIOM has developed and patented a new CPAP device for sleep apnea, portable, autonomous and mHealth , which also manages and encourages the health and care of people with this respiratory difficulty called Airmony.

AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life. They believe that OMIC technologies represent an important first step towards gaining biological insights into: How drugs work, giving them added value, reducing attrition rates and advancing through the clinic. Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Cebiotex, S.L. is a company based in Terrassa, Spain, specializing in drug delivery solutions utilizing electrospun nanofiber technology. Founded in 2012, Cebiotex focuses on the development and characterization of preclinical nonwoven nanofiber membranes designed for the controlled release of active agents. These membranes are aimed at providing local treatment options for unresectable tumors, enhancing therapeutic efficacy for patients. Through its manufacturing capabilities and contract research services, Cebiotex supports medical professionals in addressing the challenges associated with treating inoperable cancerous lesions.

The Pump it Nanotech S.L is a Start Up born from the Pump it project. This project was a response to the challenge presented by SENER, regarding the troublesome behaviour of bubbles in microfluidic devices in microgravity, during the 5th Ideas Generation Program: Aeroespacial Technologies from UAB (PRUAB).

Bioprognos is a spin-off from the Hospital Clínic of Barcelona focused on enhancing clinical outcomes and quality of life for cancer patients. The company specializes in developing innovative, non-invasive diagnostic solutions that are both accurate and cost-effective. Bioprognos offers test services aimed at the early detection and effective management of cancer by utilizing Multiple Biomarkers Disease Activity Algorithms (MBDAAs). These algorithms facilitate the qualitative detection of various neoplasia-associated biomarkers present in body fluids. Through their simple blood tests, Bioprognos provides essential information to patients and healthcare professionals, enabling informed decision-making regarding cancer and other related conditions.

Braingaze S.L., founded in 2013 and based in Canet de Mar, Spain, specializes in developing mind tracking solutions that address cognitive disorders. The company offers a range of applications, including BGaze Clinical for diagnosing ADHD in children, BGaze Consumer Insight for understanding consumer preferences through gaze analysis, and BGaze Education to enhance learning and study skills. Utilizing a patented neuro-biomarker that detects small involuntary eye movements triggered by functional games, Braingaze employs advanced algorithms, including Deep Learning, to analyze these signals. Its solutions are designed for both clinical and commercial use, targeting conditions such as ADHD and pre-symptomatic stages of Alzheimer's disease. The tools are CE Mark certified as medical devices and have been shown to significantly reduce symptoms. Braingaze continues to advance its pipeline with detection, diagnostic, and digital therapy solutions.

Cebiotex, S.L. is a company based in Terrassa, Spain, specializing in drug delivery solutions utilizing electrospun nanofiber technology. Founded in 2012, Cebiotex focuses on the development and characterization of preclinical nonwoven nanofiber membranes designed for the controlled release of active agents. These membranes are aimed at providing local treatment options for unresectable tumors, enhancing therapeutic efficacy for patients. Through its manufacturing capabilities and contract research services, Cebiotex supports medical professionals in addressing the challenges associated with treating inoperable cancerous lesions.

Capital Cell is a European equity crowdfunding platform specializing in biotechnology and life sciences. Established in 2014 and based in Barcelona, Spain, the platform connects entrepreneurs with private investors globally, including venture capitalists, business angels, and accredited investors. By integrating diverse funding sources, Capital Cell aims to create a collaborative environment for companies and researchers dedicated to advancing medical science.

QMENTA is a cloud-based platform focused on medical image analysis and visualization, specifically aimed at enhancing the diagnosis and treatment of brain diseases. By enabling specialists such as neurologists, neurosurgeons, and neuroradiologists to upload and process medical images through a user-friendly interface, QMENTA facilitates advanced analyses and visualization without the need for software installation. The platform houses patented, AI-powered analytical algorithms alongside a marketplace of partnered algorithms, allowing for efficient data management and insights extraction from large-scale brain images. Additionally, it supports compliance with regulatory standards, ensuring the privacy and security of patient data. Researchers worldwide utilize QMENTA's scalable platform to advance their understanding and analysis of extensive image datasets, ultimately accelerating the development of new treatments for brain conditions.

ZeClinics is a biotechnology start-up that provides an outsourcing solution for safety and efficacy screenings of novel chemical compounds, utilizing zebrafish as a model organism. The company has developed a platform that tracks toxicity data and preserves embryos of marine species, primarily focusing on the use of zebrafish larvae for toxicology screening. This innovative approach enables biotechnologists to assess the toxicity of drugs and related protein molecules, facilitating accurate dosage recommendations and enhancing drug development processes. By leveraging the unique biological properties of zebrafish, ZeClinics aims to streamline the evaluation of new pharmaceuticals and contribute to advancements in the field of drug safety.

Developing a genetic test to help reduce the risk of hospital infections.